CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)		12 Months Ended
		Dec. 31, 2017		Dec. 31, 2016	Dec. 31, 2015
REVENUE:
Dental practice revenue		$ 56,647,595		$ 57,167,491	$ 59,134,356
Capitation revenue		4,064,809		4,594,803	4,709,481
Total revenue		60,712,404		61,762,294	63,843,837
DIRECT EXPENSES:
Clinical salaries and benefits		37,521,910		37,202,203	38,209,674
Dental supplies		2,641,069		2,820,462	2,965,182
Laboratory fees		3,600,542		3,489,225	3,288,426
Occupancy		6,409,158		6,279,180	5,948,384
Advertising and marketing		619,642		658,487	862,397
Depreciation and amortization		3,573,983		3,993,299	4,283,291
General and administrative		5,484,758		5,477,903	5,387,988
Total direct expense		59,851,062		59,920,759	60,945,342
Contribution from dental offices		861,342		1,841,535	2,898,495
CORPORATE EXPENSES:
General and administrative	[1]	3,850,624		3,516,657	3,677,547
Stock grant		175,000	[2]	0	0
Depreciation and amortization		161,235		210,813	241,588
OPERATING LOSS		(3,325,517)		(1,885,935)	(1,020,640)
OTHER INCOME / (EXPENSE):
Change in fair value of contingent liabilities		0		0	100,000
Interest (expense), net		(443,640)		(253,940)	(105,062)
LOSS BEFORE INCOME TAXES		(3,769,157)		(2,139,875)	(1,025,702)
Income tax benefit		(1,119,926)		(753,973)	(321,032)
NET LOSS		$ (2,649,231)		$ (1,385,902)	$ (704,670)
Net loss per share of Common Stock - Basic (in dollars per share)		$ (1.42)		$ (0.74)	$ (0.38)
Net loss per share of Common Stock - Diluted (in dollars per share)		(1.42)		(0.74)	(0.38)
Cash dividends per share of Common Stock (in dollars per share)		$ 0		$ 0	$ 0.88
Weighted average number of shares of Common Stock and dilutive securities:
Basic (in shares)		1,868,138		1,860,316	1,860,246
Diluted (in shares)		1,868,138		1,860,316	1,860,246

[1] Corporate expense - general and administrative includes $229,093 of stock-based compensation expense pursuant to ASC Topic 718 for the year ended December 31, 2015, $177,679 of stock-based compensation expense pursuant to ASC Topic 718 for the year ended December 31, 2016 and $270,207 of stock-based compensation expense pursuant to ASC Topic 718 for the year ended December 31, 2017.

[2] The Company issued 12,500 shares of Common Stock under a settlement agreement with an activist shareholder group. The shares were valued at $175,000 based on the closing price of the Common Stock on the date of the grant.